Introduction：Basic information about CAS 862505-00-8|Ralimetinib, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Ralimetinib |
|---|
| CAS Number | 862505-00-8 | Molecular Weight | 420.53 |
|---|
| Density | 1.2±0.1 g/cm3 | Boiling Point | 634.4±65.0 °C at 760 mmHg |
|---|
| Molecular Formula | C24H29FN6 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 337.5±34.3 °C |
|---|
Names
| Name | 5-[2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine |
|---|
| Synonym | More Synonyms |
|---|
Ralimetinib BiologicalActivity
| Description | Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc[1]. |
|---|
| Related Catalog | Research Areas >>CancerSignaling Pathways >>MAPK/ERK Pathway >>p38 MAPKResearch Areas >>Inflammation/Immunology |
|---|
| Target | p38β MAPK:3.2 nM (IC50) p38α MAPK:5.3 nM (IC50) |
|---|
| References | [1]. Campbell RM, et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther. 2014 Feb;13(2):364-74. |
|---|
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|
| Boiling Point | 634.4±65.0 °C at 760 mmHg |
|---|
| Molecular Formula | C24H29FN6 |
|---|
| Molecular Weight | 420.53 |
|---|
| Flash Point | 337.5±34.3 °C |
|---|
| Exact Mass | 420.243774 |
|---|
| PSA | 86.14000 |
|---|
| LogP | 4.94 |
|---|
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
|---|
| Index of Refraction | 1.631 |
|---|
| InChIKey | XPPBBJCBDOEXDN-UHFFFAOYSA-N |
|---|
| SMILES | CC(C)(C)Cn1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)nc21 |
|---|
Synonyms
| UNII-73I34XW4HD |
| 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine |
| Ralimetinib |
| 3-(2,2-Dimethylpropyl)-5-[4-(4-fluorophenyl)-2-(2-methyl-2-propanyl)-1H-imidazol-5-yl]-3H-imidazo[4,5-b]pyridin-2-amine |
| LY2228820 |
| 5-(2-(tert-butyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-amine |
| 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- |
